Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

The relation between depression and parkin genotype: the CORE-PD study.

Srivastava A, Tang MX, Mejia-Santana H, Rosado L, Louis ED, Caccappolo E, Comella C, Colcher A, Siderowf A, Jennings D, Nance M, Bressman S, Scott WK, Tanner C, Mickel S, Andrews H, Waters C, Fahn S, Cote L, Frucht S, Ford B, Alcalay RN, Ross B, Orbe Reilly M, Rezak M, Novak K, Friedman JH, Pfeiffer RD, Marsh L, Hiner B, Merle D, Ottman R, Clark LN, Marder K.

Parkinsonism Relat Disord. 2011 Dec;17(10):740-4. doi: 10.1016/j.parkreldis.2011.07.008.

2.

Neuropsychological Profile of Parkin Mutation Carriers with and without Parkinson Disease: The CORE-PD Study.

Caccappolo E, Alcalay RN, Mejia-Santana H, Tang MX, Rakitin B, Rosado L, Louis ED, Comella CL, Colcher A, Jennings D, Nance MA, Bressman S, Scott WK, Tanner CM, Mickel SF, Andrews HF, Waters C, Fahn S, Cote LJ, Frucht S, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer RF, Marsh L, Hiner B, Siderowf AD, Ross BM, Verbitsky M, Kisselev S, Ottman R, Clark LN, Marder KS.

J Int Neuropsychol Soc. 2011 Jan;17(1):91-100. doi: 10.1017/S1355617710001190. Epub 2010 Nov 24.

3.

A multidisciplinary study of patients with early-onset PD with and without parkin mutations.

Lohmann E, Thobois S, Lesage S, Broussolle E, du Montcel ST, Ribeiro MJ, Remy P, Pelissolo A, Dubois B, Mallet L, Pollak P, Agid Y, Brice A; French Parkinson's Disease Genetics Study Group.

Neurology. 2009 Jan 13;72(2):110-6. doi: 10.1212/01.wnl.0000327098.86861.d4. Epub 2008 Nov 5.

4.

Olfaction in Parkin single and compound heterozygotes in a cohort of young onset Parkinson's disease patients.

Malek N, Swallow DM, Grosset KA, Lawton MA, Smith CR, Bajaj NP, Barker RA, Ben-Shlomo Y, Bresner C, Burn DJ, Foltynie T, Morris HR, Williams N, Wood NW, Grosset DG; PRoBaND Investigators.

Acta Neurol Scand. 2016 Oct;134(4):271-6. doi: 10.1111/ane.12538. Epub 2015 Dec 1.

PMID:
26626018
5.

Predictors of parkin mutations in early-onset Parkinson disease: the consortium on risk for early-onset Parkinson disease study.

Marder KS, Tang MX, Mejia-Santana H, Rosado L, Louis ED, Comella CL, Colcher A, Siderowf AD, Jennings D, Nance MA, Bressman S, Scott WK, Tanner CM, Mickel SF, Andrews HF, Waters C, Fahn S, Ross BM, Cote LJ, Frucht S, Ford B, Alcalay RN, Rezak M, Novak K, Friedman JH, Pfeiffer RF, Marsh L, Hiner B, Neils GD, Verbitsky M, Kisselev S, Caccappolo E, Ottman R, Clark LN.

Arch Neurol. 2010 Jun;67(6):731-8. doi: 10.1001/archneurol.2010.95.

6.

Mutation analysis of the parkin and PINK1 genes in American Caucasian early-onset Parkinson disease families.

Deng H, Le W, Shahed J, Xie W, Jankovic J.

Neurosci Lett. 2008 Jan 3;430(1):18-22.

PMID:
18068301
7.

Parkin mutations and phenotypic features in Czech patients with early-onset Parkinson's disease.

Fiala O, Pospisilova L, Prochazkova J, Matejckova M, Martasek P, Novakova L, Roth J, Ruzicka E.

Neuro Endocrinol Lett. 2010;31(2):187-92.

PMID:
20424582
8.

The relationship between obsessive-compulsive symptoms and PARKIN genotype: The CORE-PD study.

Sharp ME, Caccappolo E, Mejia-Santana H, Tang MX, Rosado L, Orbe Reilly M, Ruiz D, Louis ED, Comella C, Nance M, Bressman S, Scott WK, Tanner C, Waters C, Fahn S, Cote L, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer R, Payami H, Molho E, Factor SA, Nutt J, Serrano C, Arroyo M, Pauciulo MW, Nichols WC, Clark LN, Alcalay RN, Marder KS.

Mov Disord. 2015 Feb;30(2):278-83. doi: 10.1002/mds.26065. Epub 2014 Nov 12.

9.

Heterogeneous phenotype in a family with compound heterozygous parkin gene mutations.

Deng H, Le WD, Hunter CB, Ondo WG, Guo Y, Xie WJ, Jankovic J.

Arch Neurol. 2006 Feb;63(2):273-7.

PMID:
16476817
10.

Case-control study of the parkin gene in early-onset Parkinson disease.

Clark LN, Afridi S, Karlins E, Wang Y, Mejia-Santana H, Harris J, Louis ED, Cote LJ, Andrews H, Fahn S, Waters C, Ford B, Frucht S, Ottman R, Marder K.

Arch Neurol. 2006 Apr;63(4):548-52.

PMID:
16606767
11.

Olfaction in Parkin heterozygotes and compound heterozygotes: the CORE-PD study.

Alcalay RN, Siderowf A, Ottman R, Caccappolo E, Mejia-Santana H, Tang MX, Rosado L, Louis E, Ruiz D, Waters C, Fahn S, Cote L, Frucht S, Ford B, Orbe-Reilly M, Ross B, Verbitsky M, Kisselev S, Comella C, Colcher A, Jennings D, Nance M, Bressman S, Scott WK, Tanner C, Mickel S, Rezak M, Novak KE, Friedman JH, Pfeiffer R, Marsh L, Hiner B, Clark LN, Marder K.

Neurology. 2011 Jan 25;76(4):319-26. doi: 10.1212/WNL.0b013e31820882aa. Epub 2010 Dec 29.

12.

parkin mutation analysis in clinic patients with early-onset Parkinson [corrected] disease.

Poorkaj P, Nutt JG, James D, Gancher S, Bird TD, Steinbart E, Schellenberg GD, Payami H.

Am J Med Genet A. 2004 Aug 15;129A(1):44-50. Erratum in: Am J Med Genet A. 2005 Nov 15;139(1):56.

PMID:
15266615
13.

Parkin dosage mutations have greater pathogenicity in familial PD than simple sequence mutations.

Pankratz N, Kissell DK, Pauciulo MW, Halter CA, Rudolph A, Pfeiffer RF, Marder KS, Foroud T, Nichols WC; Parkinson Study Group-PROGENI Investigators.

Neurology. 2009 Jul 28;73(4):279-86. doi: 10.1212/WNL.0b013e3181af7a33.

14.

Influence of heterozygosity for parkin mutation on onset age in familial Parkinson disease: the GenePD study.

Sun M, Latourelle JC, Wooten GF, Lew MF, Klein C, Shill HA, Golbe LI, Mark MH, Racette BA, Perlmutter JS, Parsian A, Guttman M, Nicholson G, Xu G, Wilk JB, Saint-Hilaire MH, DeStefano AL, Prakash R, Williamson S, Suchowersky O, Labelle N, Growdon JH, Singer C, Watts RL, Goldwurm S, Pezzoli G, Baker KB, Pramstaller PP, Burn DJ, Chinnery PF, Sherman S, Vieregge P, Litvan I, Gillis T, MacDonald ME, Myers RH, Gusella JF.

Arch Neurol. 2006 Jun;63(6):826-32.

PMID:
16769863
15.

Parkin dosage mutations in patients with early-onset sporadic and familial Parkinson's disease in Chinese: an independent pathogenic role.

Wang C, Ma H, Feng X, Xie S, Chan P.

Brain Res. 2010 Oct 28;1358:30-8. doi: 10.1016/j.brainres.2010.08.060. Epub 2010 Aug 26.

PMID:
20800584
16.

Parkin and PINK1 mutations in early-onset Parkinson's disease: comprehensive screening in publicly available cases and control.

Brooks J, Ding J, Simon-Sanchez J, Paisan-Ruiz C, Singleton AB, Scholz SW.

J Med Genet. 2009 Jun;46(6):375-81. doi: 10.1136/jmg.2008.063917. Epub 2009 Apr 6.

17.

Mutation analysis of parkin and PINK1 genes in early-onset Parkinson's disease in China.

Zhang BR, Hu ZX, Yin XZ, Cai M, Zhao GH, Liu ZR, Luo W.

Neurosci Lett. 2010 Jun 14;477(1):19-22. doi: 10.1016/j.neulet.2010.04.026. Epub 2010 Apr 23.

PMID:
20399249
18.

Heterozygous parkin point mutations are as common in control subjects as in Parkinson's patients.

Kay DM, Moran D, Moses L, Poorkaj P, Zabetian CP, Nutt J, Factor SA, Yu CE, Montimurro JS, Keefe RG, Schellenberg GD, Payami H.

Ann Neurol. 2007 Jan;61(1):47-54.

PMID:
17187375
19.

Construction and validation of a Parkinson's disease mutation genotyping array for the Parkin gene.

Clark LN, Haamer E, Mejia-Santana H, Harris J, Lesage S, Durr A, Bs SJ, Hedrich K, Louis ED, Cote LJ, Andrews H, Fahn S, Waters C, Ford B, Frucht S, Scott W, Klein C, Brice A, Roomere H, Ottman R, Marder K.

Mov Disord. 2007 May 15;22(7):932-7.

PMID:
17415800
20.

Risk of Parkinson disease in carriers of parkin mutations: estimation using the kin-cohort method.

Wang Y, Clark LN, Louis ED, Mejia-Santana H, Harris J, Cote LJ, Waters C, Andrews H, Ford B, Frucht S, Fahn S, Ottman R, Rabinowitz D, Marder K.

Arch Neurol. 2008 Apr;65(4):467-74. doi: 10.1001/archneur.65.4.467.

Supplemental Content

Support Center